Compare BioNano Genomics Inc (BNGO) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Moody's Corporation — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Moody's Corporation trades at $479.75 (market cap $82.52B). The key difference: Moody's Corporation is far larger — about 6041× BioNano Genomics Inc's market cap, and Moody's Corporation pays a 0.86% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MCO | |
|---|---|---|
Market Cap | $13.66M | $82.52B |
Sector | Health | Financials |
52-Week High | $4.92 | $539.61 |
52-Week Low | $1.06 | $412.23 |
Enterprise Value | $16.26M | $88.54B |
Dividend Yield | — | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
MCO trades at $477.84, showing minimal daily movement (-0.06%) amid a bearish technical signal. The company demonstrates strong fundamentals with 15% revenue growth in Q2 2026 and consistent earnings beats, achieving a 34.25% net income margin. Recent news highlights institutional repositioning into credit rating companies, with MCO benefiting from robust debt issuance and AI-related analytics demand.
Outlook remains positive with a $561.88 consensus price target (17.6% upside), though valuation multiples appear elevated. Key risks include competitive pressures and market sensitivity to credit cycles. The combination of strong profitability, analyst support (56% buy ratings), and strategic positioning in credit analytics supports a constructive view despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
